{"id":333482,"date":"2026-02-20T00:00:00","date_gmt":"2026-02-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0001-2024-biopharma-breast-cancer-landscape-forecast-disease-landscape-forecast-g7\/"},"modified":"2026-03-31T10:23:27","modified_gmt":"2026-03-31T10:23:27","slug":"dlsfon0001-2026-biopharma-breast-cancer-landscape-forecast-disease-landscape-forecast-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0001-2026-biopharma-breast-cancer-landscape-forecast-disease-landscape-forecast-g7\/","title":{"rendered":"Breast Cancer &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>CDK4\/6 inhibitors (Pfizer\u2019s palbociclib, Novartis\u2019s ribociclib, and Eli Lilly\u2019s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive \/ HER2-negative disease, and we expect them to drive robust sales in the early-stage setting. Novel biomarker-driven therapies (Novartis&#8217;s alpelisib, AstraZeneca\u00b4s capivasertib, <span class=\"ice-ins ice-cts-1\" data-changedata=\"\" data-cid=\"3\" data-last-change-time=\"1769532401746\" data-time=\"1769532401746\" data-userid=\"51632\" data-username=\"Glenda\">Roche \/ Chugai Pharmaceutical\u2019s inavolisib<\/span><span class=\"ice-ins ice-cts-1\" data-changedata=\"\" data-cid=\"3\" data-last-change-time=\"1769532401746\" data-time=\"1769532401746\" data-userid=\"51632\" data-username=\"Glenda\">,<\/span> Menarini\u00b4s elacestrant<span class=\"ice-ins ice-cts-1\" data-changedata=\"\" data-cid=\"6\" data-last-change-time=\"1769532425236\" data-time=\"1769532423013\" data-userid=\"51632\" data-username=\"Glenda\">, and Eli Lilly\u2019s imlunestrant<\/span>) are effective treatment options, and the market will become increasingly crowded with agents seeking to tackle endocrine resistance. HER2-positive breast cancer treatment is rapidly evolving owing to approval and forecast label expansions for agents such as trastuzumab deruxtecan (Daiichi Sankyo \/ AstraZeneca), which has also emerged as a key therapy for the newly defined HER2-low and HER2-ultra-low subgroups. In triple-negative breast cancer, Merck &#038; Co.\u2019s immune checkpoint inhibitor pembrolizumab is the standard of care, <span class=\"ice-ins ice-cts-1\" data-changedata=\"\" data-cid=\"9\" data-last-change-time=\"1769532490833\" data-time=\"1769532490833\" data-userid=\"51632\" data-username=\"Glenda\">while TROP2-targeted agents (Gilead\u2019s sacituzumab govitecan and AstraZeneca \/ Daiichi Sankyo\u2019s datopotamab deruxtecan), are positioned to enter the lucrative earlier lines of <\/span><span class=\"ice-ins ice-cts-1\" data-changedata=\"\" data-cid=\"9\" data-last-change-time=\"1769532490833\" data-time=\"1769532490833\" data-userid=\"51632\" data-username=\"Glenda\">treatment<\/span>.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What is the size of clinically and commercially relevant drug-treatable breast cancer populations?<\/li>\n<li>What is the expected market impact of recent regulatory events, <span class=\"ice-ins ice-cts-1\" data-changedata=\"\" data-cid=\"2\" data-last-change-time=\"1769532351004\" data-time=\"1769532351004\" data-userid=\"51632\" data-username=\"Glenda\">such as the approvals of datopotamab deruxtecan and imlunestrant, and the label expansions for trastuzumab <\/span><span class=\"ice-ins ice-cts-1\" data-changedata=\"\" data-cid=\"2\" data-last-change-time=\"1769532351004\" data-time=\"1769532351004\" data-userid=\"51632\" data-username=\"Glenda\">deruxtecan<\/span>, on breast cancer subpopulations?<\/li>\n<li>Which are the most promising agents in the pipeline, and how will they shape the future of the breast cancer therapy market?<\/li>\n<li>What key drivers and constraints will affect the breast cancer therapy market over the forecast period?<\/li>\n<\/ul>\n<p><strong>Geography<\/strong><b>:<\/b> United States, <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, Japan<\/p>\n<p><b>Primary research:<\/b> Country-specific interviews with thought-leading medical oncologists; survey data collected for this and other Clarivate research<\/p>\n<p><b>Epidemiology:<\/b> Diagnosed incidence of breast cancer by country; histology, stage, and line of therapy, segmented into relevant drug-treatable populations<\/p>\n<p><b>Forecast:<\/b> 10-year, annualized, drug-level sales and patient share of key breast cancer therapies through 2034, segmented by brands and epidemiological subpopulations<\/p>\n<p><b>Drug treatments:<\/b> Coverage of select current and emerging therapies<\/p>\n<p><b>Product description<\/b><\/p>\n<div>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<\/div>\n<div>\n<ul class=\"BulletListStyle1 SCXW28665892 BCX0 round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n<\/div>\n","protected":false},"template":"","class_list":["post-333482","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-breast-cancer","biopharma-therapy-areas-solid-tumors","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/333482","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":7,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/333482\/revisions"}],"predecessor-version":[{"id":575194,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/333482\/revisions\/575194"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=333482"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}